Zafgen reports second death in key drug study
NEW YORK (AP) — Zafgen Inc. on Wednesday reported a second patient death in an ongoing study of its potential treatment for a rare genetic disorder linked to obesity. Beloranib is the company's lead drug candidate and is aimed at treating the rare genetic disorder called Prader Willi syndrome.